Pancreatic Cancer Research

ResearcherUC Davis Comprehensive Cancer CenterNo recent work listed

Ran Wei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2178-5014; OpenAlex author ID A5077319702. Sources: OpenAlex.

Their work

Papers
5 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 1 paper

Papers 5

  1. Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination… First author DOI 10.1016/j.neo.2021.12.004↗
  2. Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcit… Co-author DOI 10.1093/carcin/bgz170↗
  3. Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts. Co-author DOI 10.3390/cancers11101496↗
  4. Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial… Co-author DOI 10.3390/nu11081856↗
  5. CDK8 regulates the angiogenesis of pancreatic cancer cells in part via the CDK8-β-catenin-KLF2 signal axis. Co-author DOI 10.1016/j.yexcr.2018.05.033↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gerardo Guillermo Mackenzie · 4 shared papers, 2019–2022 · strength 0.61
  2. Dingyuan Luo · 2 shared papers, 2020–2022 · strength 0.35
  3. Cecilia Rodríguez Lanzi · 1 shared paper, 2022 · strength 0.22
  4. Basil Rigas · 1 shared paper, 2020 · strength 0.13
  5. Joseph F. LaComb · 1 shared paper, 2020 · strength 0.13
  6. Wei Min Xu · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.